EP Patent

EP1866298A2 — Hydroxysteroid dehydrogenase inhibitors

Assigned to Takeda California Inc · Expires 2007-12-19 · 18y expired

What this patent protects

Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.

USPTO Abstract

Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP1866298A2
Jurisdiction
EP
Classification
—
Expires
2007-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Takeda California Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.